Neuroprotective Effects and Therapeutic Potential of Dichloroacetate: Targeting Metabolic Disorders in Nervous System Diseases

Int J Nanomedicine. 2023 Dec 12:18:7559-7581. doi: 10.2147/IJN.S439728. eCollection 2023.

Abstract

Dichloroacetate (DCA) is an investigational drug used to treat lactic acidosis and malignant tumours. It works by inhibiting pyruvate dehydrogenase kinase and increasing the rate of glucose oxidation. Some studies have documented the neuroprotective benefits of DCA. By reviewing these studies, this paper shows that DCA has multiple pharmacological activities, including regulating metabolism, ameliorating oxidative stress, attenuating neuroinflammation, inhibiting apoptosis, decreasing autophagy, protecting the blood‒brain barrier, improving the function of endothelial progenitor cells, improving mitochondrial dynamics, and decreasing amyloid β-protein. In addition, DCA inhibits the enzyme that metabolizes it, which leads to peripheral neurotoxicity due to drug accumulation that may be solved by individualized drug delivery and nanovesicle delivery. In summary, in this review, we analyse the mechanisms of neuroprotection by DCA in different diseases and discuss the causes of and solutions to its adverse effects.

Keywords: dichloroacetate; energy metabolism; mitochondria; neuroprotection; oxidative stress.

Publication types

  • Review

MeSH terms

  • Amyloid beta-Peptides
  • Humans
  • Metabolic Diseases*
  • Neoplasms* / drug therapy
  • Nervous System Diseases*
  • Neuroprotective Agents* / pharmacology
  • Neuroprotective Agents* / therapeutic use

Substances

  • Neuroprotective Agents
  • Amyloid beta-Peptides

Grants and funding

This work was supported by the Natural Science Foundation of Shandong Province [ZR2016HP06]; the Science and Technology Planning Project of Traditional Chinese Medicine of Shandong Province [M-2023094]; the Shandong Medical and Health Science and Technology Development Project [2019WS605, 202104110334, 202104010549]; the Weifang Medical University Students Innovation and Entrepreneurship Training Program Project [X2021514, X2021517]; and the Weifang Science and Technology Development Project [2021YX028].